Suppr超能文献

强 CYP2D6 和 3A4 抑制剂帕罗西汀和酮康唑对坦索罗辛药代动力学和心血管安全性的影响。

Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.

机构信息

Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany.

出版信息

Br J Clin Pharmacol. 2011 Aug;72(2):247-56. doi: 10.1111/j.1365-2125.2011.03988.x.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

Tamsulosin metabolism involves both CYP2D6 and 3A4. However, data on potential drug-drug interactions between tamsulosin and inhibitors of CYP2D6 and 3A4 are limited and information on potential pharmacodynamic consequences of such pharmacokinetic interactions is missing.

WHAT THIS STUDY ADDS

This study provides information on the drug-drug interactions of tamsulosin with strong CYP2D6 and strong CYP3A4 inhibitors after single dose administration in healthy subjects.

AIM

To determine the effect of the strong CYP2D6 inhibitor paroxetine and strong CYP3A4 inhibitor ketoconazole on the pharmacokinetics and safety (orthostatic challenge) of tamsulosin.

METHODS

Two open-label, randomized, two-way crossover studies were conducted in healthy male volunteers (extensive CYP2D6 metabolizers).

RESULTS

Co-administration of multiple oral doses of 20 mg paroxetine once daily with a single oral dose of the 0.4 mg tamsulosin HCl capsule increased the adjusted geometric mean (gMean) values of C(max) and AUC(0,∞) of tamsulosin by factors of 1.34 (90% CI 1.21, 1.49) and 1.64 (90% CI 1.44, 1.85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11.4 h to 15.3 h. Co-administration of multiple oral doses of 400 mg ketoconazole once daily with a single oral dose of the 0.4 mg tamsulosin increased the gMean values of C(max) and AUC(0,∞) of tamsulosin by a factor of 2.20 (90% CI 1.96, 2.45) and 2.80 (90% CI 2.56, 3.07), respectively. The terminal half-life was slightly increased from 10.5 h to 11.8 h. These pharmacokinetic changes were not accompanied by clinically significant alterations of haemodynamic responses during orthostatic stress testing.

CONCLUSION

The exposure to tamsulosin is increased upon co-administration of strong CYP2D6 inhibitors and even more so of strong 3A4 inhibitors, but neither PK alteration was accompanied by clinically significant haemodynamic changes during orthostatic stress testing.

摘要

关于这个主题已经知道些什么

坦索罗辛的代谢既涉及 CYP2D6,也涉及 3A4。然而,关于坦索罗辛与 CYP2D6 和 3A4 抑制剂之间潜在药物相互作用的数据有限,并且缺少关于这些药代动力学相互作用潜在药效学后果的信息。

本研究增加了什么

本研究提供了在健康受试者单次给药后,强效 CYP2D6 抑制剂帕罗西汀和强效 CYP3A4 抑制剂酮康唑对坦索罗辛的药物相互作用的药代动力学和安全性(直立应激挑战)信息。

目的

确定每日多次口服 20mg 帕罗西汀与单次口服 0.4mg 盐酸坦索罗辛胶囊合用对坦索罗辛的药代动力学和安全性(直立应激挑战)的影响。

方法

在健康男性志愿者(广泛的 CYP2D6 代谢者)中进行了两项开放标签、随机、两交叉研究。

结果

每日多次口服 20mg 帕罗西汀与单次口服 0.4mg 盐酸坦索罗辛胶囊合用,使坦索罗辛的调整后的几何均数(gMean)值 Cmax 和 AUC(0,∞)分别增加了 1.34 倍(90%CI 1.21,1.49)和 1.64 倍(90%CI 1.44,1.85),并将盐酸坦索罗辛的终末半衰期(t1/2)从 11.4 小时延长至 15.3 小时。每日多次口服 400mg 酮康唑与单次口服 0.4mg 盐酸坦索罗辛合用,使坦索罗辛的 Cmax 和 AUC(0,∞)的 gMean 值分别增加了 2.20 倍(90%CI 1.96,2.45)和 2.80 倍(90%CI 2.56,3.07)。终末半衰期从 10.5 小时略有增加至 11.8 小时。这些药代动力学变化没有伴随直立应激测试期间血流动力学反应的临床显著改变。

结论

在合用强效 CYP2D6 抑制剂甚至更有效的强效 3A4 抑制剂时,坦索罗辛的暴露量增加,但这些药代动力学改变均不伴有直立应激测试期间临床显著的血流动力学变化。

相似文献

引用本文的文献

10
Clinical pharmacology of functional disorders of the urogenital system.泌尿生殖系统功能障碍的临床药理学
Br J Clin Pharmacol. 2011 Aug;72(2):183-5. doi: 10.1111/j.1365-2125.2011.04013.x.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验